OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26
OPKO Health (NASDAQ: OPK) will report operating and financial results for the three and 12 months ended December 31, 2025, after U.S. markets close on February 26, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
OPKO Health (NASDAQ: OPK) will report operating and financial results for the three and 12 months ended December 31, 2025, after U.S. markets close on February 26, 2026.
Senior management will host a business update, discuss results and provide financial guidance on a conference call and live webcast at 4:30 p.m. ET. Registration, dial-in numbers, webcast links and replay details are available for investors; telephone replay accessible through March 5, 2026.
Details
News Market Reaction – OPK
On Feb 12, the day this news came out, OPK closed 3.20% below the previous close.
Data tracked by StockTitan Argus for the Feb 12 session.
Key Figures
- Earnings report date
- February 26, 2026
- Planned Q4 and full-year 2025 results release after market close
- Quarter end date
- December 31, 2025
- Three- and 12-month period to be reported
- Conference call time
- 4:30 p.m. ET
- Start time for earnings call and webcast
- Telephone replay end
- March 5, 2026
- Date until which telephone replay is available
- U.S. dial-in
- 833-630-0584
- Domestic participant number for live conference call
- International dial-in
- 412-317-1815
- International participant number for live conference call
- Replay U.S. dial-in
- 855-669-9658
- Domestic number for telephone replay
- Replay passcode
- 2367034
- Passcode required to access telephone replay
Historical Context
-
Expanded Entera Bio partnership on oral long-acting PTH and OXM programs.
-
Participation in J.P. Morgan Healthcare Conference and investor meetings.
-
Participation in Piper Sandler Healthcare Conference with investor meetings.
-
Q3 2025 results, asset sale to Labcorp, and collaboration with Regeneron.
-
ModeX-Regeneron multispecific antibody collaboration announcement.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MIAMI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on Thursday, February 26, 2026. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast beginning at 4:30 p.m. Eastern time.
CONFERENCE CALL & WEBCAST INFORMATION
OPKO encourages participants to pre-register for the conference call using this link. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants may register at any time, including up to and after the call start time. Those unable to pre-register may participate by dialing 833-630-0584 (U.S.) or 412-317-1815 (International). A webcast of the call can also be accessed at OPKO’s Investor Relations page and here.
A telephone replay will be available until March 5, 2026, by dialing 855-669-9658 (U.S.) or 412-317-0088 (International) and providing the passcode 2367034. A webcast replay will be available beginning approximately one hour after the completion of the live conference call here.
About OPKO Health
OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.
Contacts:
Alliance Advisors IR
Yvonne Briggs, 310-691-7100
ybriggs@allianceadvisors.com
or
Bruce Voss, 310-691-7100
bvoss@allianceadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.